GSK3640254 PK Interaction with Oral Contraceptives

Phase 1, open-label, single-arm trial of fipravirimat in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing Interval at Steady State for Ethinyl Estradiol at Day 21, Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing Interval at Steady State for Levonorgestrel at Day 21 and 4 more. Started Jun 2019; status: completed.